tetano
Editor, Senior Moderator
Open Forum Infect Dis
. 2022 Jun 7;9(7)
fac282.
doi: 10.1093/ofid/ofac282. eCollection 2022 Jul.
Real-world Experience of Sotrovimab in High-risk, Immunocompromised COVID-19 Patients
Navina K Birk[SUP] 1 [/SUP], Saniya Jain[SUP] 1 [/SUP], Louis Massoud[SUP] 1 [/SUP], Diya Ramesh[SUP] 1 [/SUP], Lea Monday[SUP] 1 [/SUP], Bruce Muma[SUP] 1 [/SUP], Jonathan Williams[SUP] 1 [/SUP], George Alangaden[SUP] 1 [/SUP], Mayur Ramesh[SUP] 1 [/SUP]
Affiliations
Abstract
We completed a real-world analysis of 498 consecutive high-risk nonimmunocompromised and immunocompromised patients who received sotrovimab during the B.1.1.529 surge. Emergency department visits/hospitalizations and 30-day all-cause mortality between the 2 groups were similar. When administered early, sotrovimab is effective at preventing coronavirus disease 2019 progression in immunocompromised and nonimmunocompromised patients.
Keywords: COVID-19; immunocompromised hosts; monoclonal antibody; outcomes; sotrovimab.
. 2022 Jun 7;9(7)
fac282.doi: 10.1093/ofid/ofac282. eCollection 2022 Jul.
Real-world Experience of Sotrovimab in High-risk, Immunocompromised COVID-19 Patients
Navina K Birk[SUP] 1 [/SUP], Saniya Jain[SUP] 1 [/SUP], Louis Massoud[SUP] 1 [/SUP], Diya Ramesh[SUP] 1 [/SUP], Lea Monday[SUP] 1 [/SUP], Bruce Muma[SUP] 1 [/SUP], Jonathan Williams[SUP] 1 [/SUP], George Alangaden[SUP] 1 [/SUP], Mayur Ramesh[SUP] 1 [/SUP]
Affiliations
- PMID: 35859992
- PMCID: PMC9214182
- DOI: 10.1093/ofid/ofac282
Abstract
We completed a real-world analysis of 498 consecutive high-risk nonimmunocompromised and immunocompromised patients who received sotrovimab during the B.1.1.529 surge. Emergency department visits/hospitalizations and 30-day all-cause mortality between the 2 groups were similar. When administered early, sotrovimab is effective at preventing coronavirus disease 2019 progression in immunocompromised and nonimmunocompromised patients.
Keywords: COVID-19; immunocompromised hosts; monoclonal antibody; outcomes; sotrovimab.